Literature DB >> 10473101

Decreased Src tyrosine kinase activity inhibits malignant human ovarian cancer tumor growth in a nude mouse model.

J R Wiener1, K Nakano, R P Kruzelock, C D Bucana, R C Bast, G E Gallick.   

Abstract

The Src protein tyrosine kinase is overexpressed and activated in a number of human cancers, including some human ovarian cancers. To determine whether Src activity plays a role in ovarian tumor growth, stable derivatives of the SKOv-3 human ovarian cancer cell line that exhibited reduced Src tyrosine kinase activity were generated by transfection with an antisense c-src construct. Comparison of these cell lines with parental SKOv-3 cells and stable sense c-src vector-transfected control lines revealed no phenotypic alterations in anchorage-dependent proliferation, adherence, density saturation, or wound migration. However, reduction in Src activity was associated with altered cellular morphology, dramatically reduced anchorage-independent growth, and, when assessed for tumor development in a xenograft nude mouse model, diminished tumor growth. Furthermore, reduction of Src activity in the antisense c-src cell lines was associated with reduced vascular endothelial growth factor mRNA expression in vitro, and tumors derived from these cell lines displayed a phenotype indicative of abortive microvessel vascularization. These results strongly suggest that Src is involved in critical oncogenic pathways that modulate tumor growth from this ovarian cell line. Furthermore, this evidence suggests that as in other tumor systems, Src activity is required for vascular endothelial growth factor induction and angiogenic development.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10473101

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  28 in total

Review 1.  Investigational agents in development for the treatment of ovarian cancer.

Authors:  Shannon N Westin; Thomas J Herzog; Robert L Coleman
Journal:  Invest New Drugs       Date:  2012-06-04       Impact factor: 3.850

2.  Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma.

Authors:  Lin Zhang; Nuo Yang; Jose-Ramon Conejo Garcia; Alisha Mohamed; Fabian Benencia; Stephen C Rubin; David Allman; George Coukos
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

3.  Improved convergence of binding affinities with free energy perturbation: application to nonpeptide ligands with pp60src SH2 domain.

Authors:  D J Price; W L Jorgensen
Journal:  J Comput Aided Mol Des       Date:  2001-08       Impact factor: 3.686

4.  Effects of exogenous VEGF(165)b on invasion and migration of human lung adenocarcinoma A549 cells.

Authors:  Jing Chen; Zhenyu Li; Sheng Zhang; Ruiguang Zhang; Meera Dassarath; Gang Wu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-10-25

Review 5.  Src family kinases and paclitaxel sensitivity.

Authors:  Xiao-Feng Le; Robert C Bast
Journal:  Cancer Biol Ther       Date:  2011-08-15       Impact factor: 4.742

6.  Bosutinib versus Placebo for Autosomal Dominant Polycystic Kidney Disease.

Authors:  Vladimir Tesar; Kazimierz Ciechanowski; York Pei; Irina Barash; Megan Shannon; Ray Li; Jason H Williams; Matteo Levisetti; Steven Arkin; Andreas Serra
Journal:  J Am Soc Nephrol       Date:  2017-08-24       Impact factor: 10.121

7.  Relevant molecular markers and targets.

Authors:  Kathleen M Darcy; Russel J Schilder
Journal:  Gynecol Oncol       Date:  2006-10-10       Impact factor: 5.482

8.  Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study.

Authors:  Russell J Schilder; William E Brady; Heather A Lankes; James V Fiorica; Mark S Shahin; Xun C Zhou; Robert S Mannel; Harsh B Pathak; Wei Hu; R Katherine Alpaugh; Anil K Sood; Andrew K Godwin
Journal:  Gynecol Oncol       Date:  2012-06-16       Impact factor: 5.482

Review 9.  Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis.

Authors:  M P Kim; S I Park; S Kopetz; G E Gallick
Journal:  Cell Tissue Res       Date:  2008-09-25       Impact factor: 5.249

10.  A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer.

Authors:  Angeles Alvarez Secord; Deanna K Teoh; William T Barry; Miao Yu; Gloria Broadwater; Laura J Havrilesky; Paula S Lee; Andrew Berchuck; Johnathan Lancaster; Robert M Wenham
Journal:  Clin Cancer Res       Date:  2012-07-26       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.